EU and US could reach trade deal this weekend - Reuters
Bristol Myers reports high response rates for liso-cel in lymphoma
PRINCETON - Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with $47.64 billion in annual revenue and an impressive 74.69% gross profit margin, reported that 95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with its CAR T cell therapy lisocabtagene maraleucel (liso-cel) achieved a response, according to data presented at the 2025 International Conference on Malignant Lymphoma. According to InvestingPro analysis, the company maintains a GREAT financial health score, suggesting strong operational stability.
The primary analysis of the MZL cohort from the TRANSCEND FL study showed 62.1% of patients achieved complete response. With a median follow-up of approximately 24 months, 88.6% of responding patients maintained their response. These promising results could further strengthen Bristol Myers’ market position, with InvestingPro data showing expected net income growth this year. For detailed analysis of BMY and 1,400+ other stocks, investors can access comprehensive Pro Research Reports through InvestingPro.
The therapy demonstrated a consistent safety profile with low rates of severe side effects. Cytokine release syndrome occurred in 76% of patients, with only 4% experiencing Grade 3 cases and no Grade 4 or 5 events reported. Neurologic events were reported in 33% of patients, with 4% experiencing Grade 3 events and no Grade 4 or 5 events.
"MZL is an indolent disease but remains an area of high unmet need for patients who are relapsing and reaching later lines of treatment," said Rosanna Ricafort, vice president at Bristol Myers Squibb, according to the press release.
Marginal zone lymphoma is the third most common lymphoma, accounting for about 7% of all non-Hodgkin lymphoma cases. While initial therapy often leads to remission, relapse is common.
Liso-cel is currently approved in the United States for several types of lymphoma, including large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma.
The study enrolled adults with relapsed or refractory MZL who received liso-cel as a third-line or later treatment at a target dose of 100 x 106 CAR-positive viable T cells.
Bristol Myers Squibb reported this data based on a press release statement regarding the company’s ongoing clinical trials. The company’s current market capitalization stands at $101.25 billion, and InvestingPro’s Fair Value analysis suggests the stock is currently undervalued, presenting a potential opportunity for investors interested in the pharmaceutical sector.
In other recent news, Bristol-Myers Squibb announced that its oral medication Sotyktu demonstrated significant efficacy in treating psoriatic arthritis in a Phase 3 clinical trial. The trial showed that 54.2% of patients receiving Sotyktu achieved at least a 20% improvement in disease symptoms by Week 16. Additionally, Bristol-Myers Squibb’s subsidiary, RayzeBio, will acquire rights to develop and commercialize OncoACP3, a prostate cancer treatment, from Philochem AG in a deal potentially worth up to $1.35 billion. The acquisition includes an upfront payment of $350 million and potential milestone payments. Meanwhile, Cantor Fitzgerald maintained its neutral rating on Bristol-Myers Squibb, highlighting upcoming data for the company’s Alzheimer’s treatment as a key catalyst. Raymond James also maintained its Market Perform rating for the company following a collaboration with BioNTech on a bispecific antibody for solid tumors. Furthermore, Bristol-Myers Squibb presented new data on its targeted protein degradation platform at the European Hematology Association Congress. This included clinical findings on investigational agents for multiple myeloma and non-Hodgkin lymphoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.